The United Kingdom and the United States have reached a landmark commercial pact that will guarantee zero import taxes on UK pharmaceutical exports entering the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This move ensures that duties on these crucial goods will be held at zero for a timeframe of the next three years.
This agreement comes after recent statements to dramatically increase tariffs on patented drug imports, with potential rates discussed reaching double the cost.
"This deal with the United Kingdom bolsters the global environment for new treatments and establishes long-overdue fairness to transatlantic medicine commerce," a statement noted.
Commercial Impact
Medicines constitute one of the the United Kingdom's biggest goods shipped to the America, which is easily the largest destination for large British pharmaceutical firms.
Export figures reveal that in the 12 months prior to the third quarter, the UK exported pharmaceutical products totaling £11.1bn to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This agreement secures work, increases investment and sets the stage for the UK to become a worldwide center for biotech and pharma," a minister remarked.
Specific NHS Changes
The deal entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a aim to raise total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, repayments topped twenty percent.
Industry Background
The deal follows a ongoing dispute between the sector and the ministers over spending levels and regulatory access.
The disagreement were intensified by assertions that US patients were charged several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or cancelled, while major investments have been announced toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a share of its resources over the previous ten-year period.
